MENUNews Archive
Date: 01/09/2020
The University of Michigan Rogel Cancer has named Bhramar Mukherjee, Ph.D., associate director for quantitative data sciences, and Christopher Friese, Ph.D., R.N., associate director for cancer control and population sciences.
Date: 12/28/2019
Across the country, new and experimental therapies are available to patients with cancer through clinical trials. The effectiveness of a new drug or treatment approach is often evaluated based on measurements of changes seen in patients’ tumors using a variety of imaging techniques — such as MRI, CT and PET scans.
Date: 12/13/2019
Recently, the Food and Drug Administration recommended that patients considering breast implants — whether for reconstructive surgery after a mastectomy or cosmetic surgery — receive detailed information about potential complications and rare health risks that can occur.
Date: 12/06/2019
The Cancer Network of West Michigan is an initiative to integrate cancer care services in West Michigan formed by Mercy Health, Metrol Health, the University of Michigan Health and Michigan Medicine providing patients in western Michigan access to advanced, state-of-the-art, comprehensive diagnosis, treatment and support.
Date: 12/05/2019
The 2019 ASH Annual Meeting and Exposition will feature more than 30 presentations by University of Michigan faculty and trainees.
Date: 12/04/2019
A new study makes a case for getting screened every year instead of every other year. Women diagnosed with breast cancer after receiving yearly mammograms had smaller tumors and less-advanced disease than women who had mammograms every other year.
Date: 11/27/2019
The six U-M Rogel Cancer Center members are: Dr. Maria G. Castro, Dr. Jun Li, Dr. Linda C. Samuelson, Dr. Emily E. Scott, Dr. Shaomeng Wang, Dr. Weiping Zou.
Date: 11/22/2019
Between 2005 and 2015, prescriptions for gabapentinoid medications -- gabapentin and pregabalin -- to adults with cancer saw a two-fold increase, a U-M Rogel Cancer Center study has found.
Date: 11/18/2019
STAT3 has been a major therapeutic target in the treatment of cancer. But it's largely been considered “undruggable” due to the difficulty of developing compounds to effectively inhibit its activity. Researchers at the U-M Rogel Cancer Center have a new approach to targeting STAT3.
Date: 11/16/2019
A group of researchers at the U-M Rogel Cancer Center is laying the foundations for a new, “multi-omic” approach that could help determine the drugs to which a particular triple-negative tumor will be most likely to respond based on the totality of its molecular features.